• Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline
Print

News

  • Joint Industry Statement for WHO's Executive Board Meeting 154 (January 2024)

    We welcome the Executive Board (EB) report on noncommunicable diseases (NCDs) and WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. With childhood obesity and diabetes on an alarming rise, alongside population ageing, urbanization, climate

    Read More
  • IGBA General Statement on WHO's Executive Board Meeting 154 (January 2024)

    The International Generic and Biosimilar Medicines Association (IGBA), giving voice to the manufacturers of quality-assured, safe, and cost-effective generic and biosimilar medicines, welcomes the World Health Organization Executive Board’s focus on the Three Billion Targets in the EB154 agenda, linking

    Read More
  • IGBA Open Letter concerning the INB negotiations of the Pandemic Agreement (January 2024)

    The generic and biosimilar medicines industry globally, represented by the International Generic and Biosimilar medicines Association (IGBA), supplies the overwhelming majority of prescription medicines to patients worldwide, and strongly supports ongoing multilateral efforts to achieve a robust WHO Pandemic Agreement.

    Read More
  • IGBA Comments to the 30 October 2023 Proposal for negotiating text of the Pandemic Agreement (January 2024)

    IGBA welcomes the opportunity to provide comments to the 30 October 2023 proposal for negotiating text of the WHO Pandemic Agreement. As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States

    Read More
  • IGBA announces leadership change (January 2024)

    The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Suzette Kox, the first IGBA Secretary General, has passed on the baton to Dr. Susana Almeida.

    Read More
  • Vinita Gupta and Lucas Sigman appointed 2024 Chair and Vice-Chair of the IGBA CEO Advisory Committee (December 2023)

    The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Vinita Gupta, CEO of Lupin, was appointed Chair and Lucas Sigman, CEO of Insud Pharma, Vice-Chair.

    Read More
  • IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care (November 2023)

    Geneva, November 13, 2023 – In the week ahead, IGBA will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines which contribute to delivering better health outcomes and biologics access equity for more patients. The

    Read More
  • IGBA and WHO collaborate on expanding access to quality-assured generic and biosimilar medicines (October 2023)

    On October 27, 2023, the International Generics and Biosimilars Medicines Association (IGBA), including members of IGBA’s CEO Advisory Committee, met with World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus in Geneva. During the full-day meeting, IGBA company and member

    Read More
  • IGBA’s CEO Advisory Committee Meets with WIPO Director General Daren Tang (October 2023)

    The International Generic and Biosimilar Medicines Association’s (IGBA) CEO Advisory Committee held an exchange with Mr. Daren Tang, Director General of the World Intellectual Property Organization (WIPO). This was the first opportunity for Mr. Tang to engage in a direct

    Read More
  • ANAFAM, the National Association of Medicines Manufacturers of Mexico, joins IGBA (September 2023)

    IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that ANAFAM has been accepted and welcomed as a new IGBA Associate Member.

    Read More
  • Global regulators and biopharmaceutical and vaccine industry to share experiences with managing pharmaceutical quality systems (July 2023)

    On 20 July 2023, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a virtual workshop on the development of a global Pharmaceutical Quality Knowledge Management System (PQ KMS), which aims to facilitate the exchange of knowledge related to

    Read More
  • IGBA Welcomes ICH New Topic for Harmonisation: “Bioequivalence for Modified-Release Products” (June 2023)

    The International Generic and Biosimilar Medicines Association ( IGBA ) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ( ICH ) for its adoption of a new topic focused on the harmonisation of " Bioequivalence

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

Share this page!

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on: Twitter - LinkedIn - YouTube

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site